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Pneumocystis jirovecii pneumonia (PJP) is a severe
complication and leading cause of death among human
immunodeficiency virus (HIV)-infected patients.1 Although
trimethoprim/sulfamethoxazole (TMP/SMZ) is well known
for its effectiveness as empiric and target therapy, it is also
associated with various side effects (including skin rash,
leukopenia, hepatitis, and diarrhea).1,2 The clinical evi-
dence of the synergistic activity of caspofungin to TMP/SMZ
or salvage treatment of PJP remains controversial to date.
Here, we report an HIV-infected patient complicated with
PJP who had skin rash and leukopenia after TMP/SMZ
treatment for 6 days. Consequently, the treatment regimen
was replaced with caspofungin. The patient was discharged
from the hospital in good condition after 14 days of cas-
pofungin salvage therapy.
A 46-year-old male patient was admitted to the hospital
for high fever and dyspnea, representing a fresh case of HIV
infection with very low CD4 count (36/mL). His chest
radiograph showed bilateral interstitial infiltration of lung
fields (Figure 1A), and the computed tomography scan
revealed bilateral diffuse ground-glass infiltrates
(Figure 1B). A bronchoalveolar lavage specimen analyzed by
Gomori methenamine silver staining revealed a cluster of P.
jirovecii cysts. The patient was initially administered with
TMP/SMZ (160/800 mg, q6h) intravenously. He received oral
prednisolone (30 mg daily) as adjunctive therapy for PJP.
The patient’s white blood cell count decreased from 5700/
mL to 3200/mL, and skin rash developed on the 7th admis-
sion day. The TMP/SMZ treatment was discontinued, and
caspofungin was administered at a loading dose of 70 mg
intravenously and a maintenance dosage of 50 mg daily.
The patient received caspofungin therapy for a total of 14
days, and the subsequent chest X-ray (Figure 1C) demon-
strated a significant improvement. The patient received
HAART (highly active antiretrovirus therapy) regimen with
combivir (lamivudine/zidovudine) þ stocrit (efavirenz) at
the time of caspofungin therapy. His CD4 count recoveredPlease cite this article in press as: Lee W-S, et al., Caspofungin sa
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secondary prophylaxis of PJP at discharge.
The assembly of the cell wall of P. jirovecii showed the
presence of (1,3)-b-D-glucan in its cell wall component.2e4
Echinocandins do not like azoles and polyenes affecting
the ergosterol receptors of the cell membrane, as its
antifungal activity is targeting the cell wall of PJP. In the
past decade, echinocandins have proven efficacious for
antifungal treatment in invasive candidiasis and aspergil-
losis.5 In animal models of PJP infections, echinocandins
have demonstrated prophylactic and therapeutic effec-
tiveness.2,3 However, caspofungindwhether it is an effec-
tive treatment for P. jirovecii pneumonia in
immunocompromised patients without HIV infectiondis
also controversial.4 Hong et al4 reported four HIV-negative
immunocompromised patients with PJP infections who
received caspofungin as a salvage regimen at Asan Medical
Center (Seoul, South Korea), and none of them showed a
positive response. However, Tu et al3 reported three cases
of renal transplant recipients with PJP who were treated
with caspofungin combined with low-dose TMP/SMZ as
salvage therapy, and all exhibited a good response. Another
clinical trial involving caspofungin salvage treatment of PJP
in HIV-infected patients has shown a high success rate (80%,
8/10 patients).2 These conflicting findings could be partially
explained by the differences in the underlying disease of
the patients, variations in the severities of PJP, and the
timing of effective antimicrobial therapy.6 Lee et al6 re-
ported that, based on a retrospective review of 43 immu-
nocompromised patients (including 23 HIV-infected
patients), the presence of pulmonary disease, absence of
HIV infection, and a delay of anti-PJP therapy were asso-
ciated with crude mortality. However, early diagnosis and
early treatment of PJP and subsequent appropriate therapy
would improve the outcome of PJP in HIV-infected patients.
In our HIV-infected patient, the positive clinical effect of
salvage therapy with caspofungin was observed; however,
randomized controlled studies of caspofungin alone orlvage therapy in Pneumocystis jirovecii pneumonia, Journal of
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Figure 1. (A) Chest radiograph shows bilateral interstitial infiltration of lung fields. (B) Computed tomography scan exhibits
bilateral diffuse ground-glass picture. (C) Follow-up chest X-ray shows improvement after caspofungin complete therapy.
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+ MODELcombined with TMP/SMZ as salvage therapy for PJP are
warranted to verify this finding.
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